CSIMarket
 


Aimmune Therapeutics Inc   (AIMT)
Other Ticker:  
 
 

AIMT's Income from Cont. Operations Growth by Quarter and Year

Aimmune Therapeutics Inc 's Income from Cont. Operations results by quarter and year




AIMT Income from Cont. Operations (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - -66.90 -77.76 -41.17
III Quarter September - -64.46 -51.70 -31.79
II Quarter June -69.24 -62.88 -52.55 -32.50
I Quarter March -86.43 -54.27 -49.50 -25.87
FY   -155.67 -248.51 -231.51 -131.33



AIMT Income from Cont. Operations second quarter 2020 Y/Y Growth Comment
Aimmune Therapeutics Inc in the second quarter 2020 recorded loss from continued operations of $ -69.24 millions.

According to the results reported in the second quarter 2020, Aimmune Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Aimmune Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter 2020.




AIMT Income from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Aimmune Therapeutics Inc 's second quarter 2020 Income from Cont. Operations $ -69.24 millions AIMT's Income Statement
Aimmune Therapeutics Inc 's second quarter 2019 Income from Cont. Operations $ -62.88 millions Quarterly AIMT's Income Statement
New: More AIMT's historic Income from Cont. Operations Growth >>


AIMT Income from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Aimmune Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AIMT's II. Quarter Q/Q Income from Cont. Operations Comment
Although Aimmune Therapeutics Inc in the II. Quarter 2020 admitted loss from continued operations of $ -69.24 millions, some analyst said, that those numbers point to slight up side relative to the -86.43 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Aimmune Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Aimmune Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AIMT's II. Quarter Q/Q Income from Cont. Operations Comment
Although Aimmune Therapeutics Inc in the II. Quarter 2020 revealed loss from continued operations of $ -69.24 millions, management point out, that those numbers point to recovery compare to the -86.43 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Aimmune Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Aimmune Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Aimmune Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
Cumulative Income from Cont. Operations 12 Months Ending $ -287.03 $ -280.66 $ -248.50 $ -259.36 $ -246.60
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Aimmune Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -287 millions in the Jun 30 2020 period.
The results are worsening as the cumulative loss from continued operations is becoming larger from $ -280.66 millions in TTM ending quarter Mar 31 2020 and $ -236.278 millions from the TTM period ending Jun 30 2019.

Aimmune Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Aimmune Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -287 millions in the Jun 30 2020 period.
The business is getting worse as the cumulative loss from continued operations is inflating from $ -280.66 millions in the twelve months ending a quarter before and $ -236.278 millions for the twelve months ending in the quarter Jun 30 2019.

Aimmune Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
AIMT's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for AIMT's Competitors
Income from Cont. Operations Growth for Aimmune Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for AIMT's Customers

You may also want to know
AIMT's Annual Growth Rates AIMT's Profitability Ratios AIMT's Asset Turnover Ratio AIMT's Dividend Growth
AIMT's Roe AIMT's Valuation Ratios AIMT's Financial Strength Ratios AIMT's Dividend Payout Ratio
AIMT's Roa AIMT's Inventory Turnover Ratio AIMT's Growth Rates AIMT's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jun 30 2020 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2020
Merck and Co Inc 13.84%$ 13.843 millions
3m Company13.79%$ 13.793 millions
Select Medical Holdings Corp12.50%$ 12.503 millions
Biogen Inc 7.52%$ 7.523 millions
Eli Lilly And Company6.39%$ 6.389 millions
Universal Health Services Inc 6.32%$ 6.316 millions
Supernus Pharmaceuticals inc 5.93%$ 5.928 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com